NCT06890585View on ClinicalTrials.gov

Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
BTK InhibitorsHistone Deacetylase InhibitorDouble Express Diffuse Large B-cell Lymphoma
Interventions
DRUG

ZCR-CHOP

Zanubrutinib, Chidamide, and Rituximab Induction Therapy Sequentially Combined With or Without CHOP

DRUG

R-CHOP

R-CHOP

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Li Zhiming

OTHER